市場概況

The global hepatocellular carcinoma (HCC) treatment market is projected to reach USD 8.05 10億まで 2029, growing at a CAGR of 13.4% から 2023 に 2029. HCC is the most common type of liver cancer, 会計 89% of cases. It has a low survival rate of less than 5% and is influenced by factors like hepatitis, aflatoxin exposure, and liver cirrhosis. The HCC treatment pipeline includes over 155 assets, with PD-1 and PD-L1 inhibitors being dominant. There are 220 clinical trials for HCC treatment, with the US leading. Biologics targeting PD-1 and PD-L1 have gained traction. The introduction of five new agents is expected to drive market growth. Therapeutic agents targeting PD-1 and PD-L1 have shown effectiveness in HCC, and innovation and technological advancements are expected to improve outcomes.

レポートは市場規模と成長をカバーしています, セグメンテーション, 競争環境, trends and strategies for global hepatocellular carcinoma treatment market. 利害関係者が現在の市場機会を活用できるように、市場の定量的な分析を提供します。. このレポートはまた、市場動向と主要な競合他社のアプローチに基づいて、機会と戦略の上位セグメントを特定します。.

市場セグメンテーション

市場はさまざまな要因に基づいて分割されます, including drug class, gender type, 年齢層, そして地理.
Drug class: 化学療法, 標的療法
Gender: 男性, 女性
年齢層: 下に 29 years, 30-49 years, 50+ years

地理によるセグメンテーション
北米 - 私たち
ヨーロッパ - ドイツ, フランス, イギリス, イタリア, スペイン
アジア太平洋 – 中国, 日本

Chemotherapeutic drugs will remain dominant in the global HCC therapeutics market, but targeted therapies are expected to grow rapidly. The approval of biologics like Tecentriq (Atezolizumab) will drive the HCC treatment market. Research into novel mechanisms of action (MOAs) aims to address treatment non-response. The launch of new drugs targeting moderate-to-severe patients will drive market growth. Biologics targeting PD-1 and PD-L1 are gaining popularity.

Men will have a significant share in the HCC treatment market due to higher prevalence. の 50 years and above age group dominates the market.

The United States is the leading market due to affordability, awareness, とテクノロジー. China will experience fast growth due to improved healthcare access and expenditure. The US holds a significant market share of 48.3% in the HCC treatment market among the eight major markets.

競争環境

The global HCC treatment market has numerous companies offering generic and patented drugs. The FDA approved Nivolumab, Keytruda, and Tecentriq for HCC treatment. Biologics and targeted therapies are changing the treatment landscape. Key players include Abbisko Therapeutics Co., 株式会社, Advenchen Laboratories, 合同会社, Akeso, 株式会社, AstraZeneca plc, バイエルAG, BeiGene, 株式会社, Bristol-Myers Squibb Company, エリ・リリーと会社, Exelixis, 株式会社, F. ホフマン・ラ・ロシュAG, Genoscience Pharma SAS, 革新的な生物学, 株式会社, Jiangsu Hengrui Pharmaceuticals Co., 株式会社, メルク & 株式会社, 株式会社, Novra Technologies Inc., Pfizer Inc., サノフィS.A., Shanghai Henlius Biotech Inc., Surface Oncology, 株式会社, Suzhou Zelgen Biopharmaceuticals Co., 株式会社, TaiRx, 株式会社, Virogin Biotech Ltd., and Yiviva Inc. These companies invest in research, コラボレーション, 買収, and innovation to compete in the market.

最近の業界の発展

Roche announced in May 2020 that the Food and Drug Administration approved the use of atezolizumab in combination with bevacizumab (Tecentriq) for the treatment of unresectable or metastatic hepatocellular carcinoma in patients without prior systemic therapy. This approval was based on findings from the international IMbrave150 (NCT03434379) trial, which involved patients with locally advanced unresectable or metastatic hepatocellular carcinoma who had not received prior systemic therapy.

5月に 2019, Eli Lilly and Company announced that the Food and Drug Administration approved ramucirumab (Cyramza) as a standalone treatment for hepatocellular carcinoma (HCC) in patients with an alpha-fetoprotein (AFP) level of ≥ 400 ng/mL who had previously been treated with sorafenib. This approval was based on data from the REACH-2 (NCT02435433) study, a double-blind, placebo-controlled, multinational trial conducted in 292 patients with advanced HCC and AFP levels ≥ 400 ng/mL who had experienced disease progression on or after sorafenib treatment or were intolerant to it.

報告書の範囲

To analyze and forecast the market size of the global hepatocellular carcinoma treatment market.
To classify and forecast the global hepatocellular carcinoma treatment market based on drug class, gender, 年齢層, 地理.
To identify drivers and challenges for the global hepatocellular carcinoma treatment market.
合併などの競争展開を検討するため & 買収, 協定, コラボレーションとパートナーシップ, 等, in the global hepatocellular carcinoma treatment market.
To identify and analyze the profile of leading players operating in the global hepatocellular carcinoma treatment market.

このレポートを選択する理由

Gain a reliable outlook of the global hepatocellular carcinoma treatment market forecasts from 2023 に 2029 シナリオ全体にわたって.
投資対象となる成長セグメントを特定する.
会社概要と市場データを通じて競合他社に先んじる.
Excel 形式でのシナリオ全体の分析を容易にするための市場予測.
3ヶ月間の戦略コンサルティングとリサーチサポート.
シングルユーザーライセンスに提供される印刷認証.